Paratek Pharmaceuticals, Inc. Announces Participation in Ladenburg Thalmann 2015 Healthcare Conference

BOSTON, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced that its President and Chief Medical Officer, Evan Loh, MD, will participate in the Ladenburg Thalmann 2015 Healthcare Conference. Dr. Loh will present on Tuesday, September 29 from 10:30 to 10:55 a.m. The conference will be at the Sofitel New York, in New York City. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry.

To access the live webcast of Paratek's presentation, please visit http://wsw.com/webcast/ladenburg/prtk. Please connect to the web site at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast can be accessed for a minimum of 30 days and will be available approximately 24 hours after the live presentation.

About Paratek

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Paratek initiated a Phase 3 registration study in ABSSSI in June to determine the efficacy and safety of omadacycline compared to linezolid. A Phase 3 registration study for CABP with omadacycline is planned to be initiated before the end of 2015.

Omadacycline is a new once-daily oral and IV, well-tolerated broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), urinary tract infections (UTI), and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a new once-daily oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline was designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Two identical Phase 3 registration studies were initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.

For more information, visit www.paratekpharm.com.

Forward Looking Statements

The statement in this press release that a Phase 3 registration study for CABP with omadacycline is planned to be initiated before the end of 2015 is a forward-looking statement. This forward-looking statement is based upon Paratek's current expectations and involve substantial risks and uncertainties. The Phase 3 registration study for CABP with omadacycline may not be initiated on the time frame indicated, or at all, as a result of these risks and uncertainties, which include, without limitation, risks related to: (i) the ability to receive regulatory approvals; and (ii) unexpected results obtained in the clinical studies. These and other risk factors are discussed under "Risk Factors" and elsewhere in Paratek's Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, and Paratek's other filings with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.

CONTACT: Media Relations: Michael Lampe (484) 575-5040 michael@michaellampeconsulting.com Investor Relations: Hans Vitzthum LifeSci Advisors, LLC. 212-915-2568

Source:Paratek Pharmaceuticals